Overview

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque Psoriasis

Status:
Completed
Trial end date:
2019-06-12
Target enrollment:
Participant gender:
Summary
This is a multicenter, double-blind, randomized, vehicle-controlled, parallel-group proof-of-concept study designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of topically applied ESR-114 following twice daily (BID) application for 42 days (6 weeks).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Escalier Biosciences B.V.
Collaborator:
Innovaderm Research Inc.